Home โบ Blast Crisis
Blast Crisis clinical trials recruiting in the U.S.
10 studies for Blast Crisis are recruiting participants at sites across the United States.
Cities with the most studies
By state
Recently updated studies
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
RecruitingPhase 2
Ages 18 to 65 ยท All sexes ยท Updated Nov 12, 2026 ยท NCT02115295Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
RecruitingPhase 2
Ages 12 and older ยท All sexes ยท Updated Nov 10, 2026 ยท NCT03589729Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Nov 10, 2026 ยท NCT03263572Asciminib Roll-over Study
RecruitingPhase 4
Ages 7 to 100 ยท All sexes ยท Updated Nov 9, 2026 ยท NCT04877522Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 ยท All sexes ยท Updated Oct 28, 2026 ยท NCT01137643Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
RecruitingPhase 1
Ages 1 and older ยท All sexes ยท Updated Sep 18, 2026 ยท NCT03630991Registry of Older Patients With Cancer
RecruitingObservational study
Ages 65 and older ยท All sexes ยท Updated Jun 29, 2026 ยท NCT01137825HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
RecruitingPhase 1
Up to age 80 ยท All sexes ยท Updated May 18, 2026 ยท NCT03326921MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Jan 23, 2026 ยท NCT07362225Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Nov 5, 2025 ยท NCT04260022From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.